Other languages MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Delayed Nasdaq Other stock markets 12:57:52 2024-07-03 pm EDT			5-day change	1st Jan Change
0.9014 ^USD	+1.28%		+1.28%	-15.76%

Jul. 01	MiNK Therapeutics, Inc.(NasdaqCM:INKT) dropped from Russell 3000E Growth Index	CI
May. 22	MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting	May. 22
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	May. 13
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 21
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	Mar. 06
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	Feb. 14
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	Feb. 06
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	Jan. 30
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023	Nov. 03
MiNK Therapeutics, Inc. Announces Resignation of as Director	23-10-17
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
MiNK Therapeutics Says Cell Product Candidate MiNK-215 Showed 'Potent Anti-Tumor Activity' in Preclinical Trial	23-05-18
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Agenus Inc. spin-off 14.5% stake in MiNK Therapeutics, Inc. for $9.1 million.	23-04-30
Mink Therapeutics, Inc. Presents Clinical Data At Sitc 2022 Showcasing Inkt Cell Therapy Pipeline	22-11-10
MiNK Therapeutics Files for $50 Million Shelf	22-11-04
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Other languages

Filters